Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, discusses exciting research in the field of acute myeloid leukemia (AML), emphasizing the importance of conducting more studies to compare haploidentical transplantation with other types of transplantation. Prof. Nagler also explains how the introduction of novel agents, such as venetoclax, anti-CD123 monoclonal antibodies (mAbs), and FLT3 inhibitors, have revolutionized the AML treatment landscape, and the need for more data in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.